Strong Analyst Confidence in C4 Therapeutics (CCCC)'s Cemsidomide Drives 270% Upside Potential

C4 Therapeutics, Inc. (NASDAQ:CCCC) is included in our list of the 7 most volatile stocks under $5 for day trading.

As of February 16, 2026, all of the analysts who cover C4 Therapeutics, Inc. (NASDAQ:CCCC) remain bullish on the stock. Their consensus price target of $7.00 indicates a 270.37% upside, which reflects their belief in Cemsidomide, the company’s primary degrader.

On January 14, 2026, C4 Therapeutics, Inc. (NASDAQ:CCCC) laid out key clinical and regulatory milestones through 2028, including plans to achieve accelerated approval for Cemsidomide in relapsed/refractory multiple myeloma.

With an NDA submission targeted by year-end 2028 and initial ORR data anticipated in 2H 2027, C4 Therapeutics, Inc. (NASDAQ:CCCC) intends to launch the Phase 2 MOMENTUM trial in Q1 2026 for patients who are fourth-line or later. In patients with second-line or later disease, a Phase 1b combination study involving elranatamab is scheduled to start in Q2 2026, while a Phase 3 trial is anticipated by early 2028.

Based on 2025 Phase 1 data, Cemsidomide showed ORRs of 40% and 53% at 75 µg and 100 µg, respectively. With partnerships with Merck KGaA, Roche, and Biogen, C4T hopes to file up to 3 INDs by 2028 from its neuro- and inflammation programs, in addition to its oncology programs.

C4 Therapeutics, Inc. (NASDAQ:CCCC), a clinical-stage biopharmaceutical company, uses its Degronimid platform to develop small-molecule degraders that selectively eliminate disease-driving proteins in neurodegenerative, inflammatory, and cancerous diseases.

While we acknowledge the potential of CCCC as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: What Are the Best Stocks to Buy Right Now? and 10 Stocks Under $1 That Will Explode.

Disclosure: None.